CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-15 | PISKEL KYLE Chief Financial Officer | Grant or award | +7,815 | 279,325 | ||
| 2025-05-01 | ROBINS HARLAN S Chief Scientific Officer | Option exercise 10b5-1 | +68,412 | $6.32 | $432K | 1,347,936 |
| 2025-05-01 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −68,412 | $7.35 | $503K | 1,279,524 |
| 2025-05-01 | ROBINS HARLAN S Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −68,412 | 0 | ||
| 2025-03-24 | ROBINS HARLAN S Chief Scientific Officer | Option exercise 10b5-1 | +1,698 | $6.32 | $11K | 1,281,222 |
| 2025-03-24 | ROBINS HARLAN S Chief Scientific Officer | Sale 10b5-1 | −1,698 | $9.00 | $15K | 1,279,524 |
| 2025-03-24 | ROBINS HARLAN S Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,698 | 68,412 | ||
| 2025-03-14 | PISKEL KYLE Chief Financial Officer | Option exercise | +2,500 | $6.32 | $16K | 271,510 |
| 2025-03-14 | PISKEL KYLE Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −2,500 | 0 | ||
| 2025-03-13 | GRIFFIN MICHELLE RENEE Director | Sale | −36,291 | $7.19 | $261K | 15,394 |
| 2025-03-12 | HERSHBERG ROBERT Director | Sale | −53,000 | $7.59 | $402K | 69,690 |
| 2025-03-10 | NEUPERT PETER M Director | Option exercise | +50,000 | $4.07 | $204K | 234,690 |
| 2025-03-10 | NEUPERT PETER M Director | Sale | −10,000 | $7.05 | $71K | 224,690 |
| 2025-03-10 | NEUPERT PETER M Director | Option exercise · Stock Option (right to buy) | −50,000 | 0 | ||
| 2025-03-06 | ROBINS CHAD M CEO and Chairman | Sale | −102,218 | $7.64 | $781K | 2,959,249 |
| 2025-03-06 | GRIFFIN MICHELLE RENEE Director | Sale 10b5-1 | −15,664 | $7.94 | $124K | 51,685 |
| 2025-03-05 | LO FRANCIS Chief People Officer | Sale | −7,085 | $6.98 | $49K | 346,636 |
| 2025-03-05 | LO FRANCIS Chief People Officer | Sale | −13,790 | $6.99 | $96K | 332,846 |
| 2025-03-05 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Sale | −26,023 | $6.98 | $182K | 347,238 |
| 2025-03-05 | BENZENO SHARON Chief Commercial Ofc Imm Med | Sale | −41,600 | $6.98 | $290K | 395,788 |
Page 26 of 120 · 2,386 trades